Skip to main content
. 2022 May 13;10(5):E670–E678. doi: 10.1055/a-1797-9318

Table 2. Treatment outcomes.

Ascites (N = 24) No ascites (N = 31) P value
Procedure time (minutes, mean ± SD) 76.0 ± 42.5  89.0 ± 55.2 0.35
Technique (%) 0.26

  • Direct method

  3 (12.5)   4 (12.9)

  • Dual scope-assisted method

  7 (29.2)   3 (9.7)

  • Balloon-assisted method

  2 (8.3)   6 (19.4)

  • Nasobiliary catheter-assisted method

 12 (50.0)  18 (58.1)
Type of stent (%) 1.00

  • Cautery-enhanced

 24 (100.0)  30 (96.8)

  • Non-cautery-enhanced

  0 (0.0)   1 (3.2)
Clinical success (%) 22 (91.7)  29 (93.5) 1.00
30-day readmission (%)  6 (25.0)   6 (19.4) 0.62
Length of hospital stay after procedure, days, mean (SD)  4.8 ± 3.4   3.0 ± 4.1 0.13
Adverse Events, no. patients (%)  9 (37.5)   6 (19.4) 0.13
Mild  5 (20.8)   3 (9.7)

  • Mal-deployment

  1   2

  • Late stent migration after healing

  1   0

  • Abdominal pain

  2   2

  • DVT

  1   0
Moderate  2 (8.3)   3 (9.7)

  • Mal-deployment 1

 2   0

  • Abdominal pain

  0   1

  • Tissue ingrowth

  0   1

  • Cholangitis

  0   1

  • Peritonitis

  1   0

  • Sepsis

  1   0
Severe  2 (8.3)   0 (0.0)

  • Peritonitis

  1   0

  • Peritonitis and sepsis

  1   0
Recurrence of obstructive symptoms (%)  1 (4.2)   1 (3.2) 1.00
Reintervention for recurrent GOO (%)  1 (4.2)   1 (3.2) 1.00
Death (%) 14 (58.3)  17 (54.8) 0.80
Time to death (days, median (IQR)) 35.5 (18.5–92.3) 110.5 (82.3–211.5) 0.005 2
Duration of follow-up (days, median (IQR)) 73.5 (20.3–291.8) 106.0 (77.0–200.0) 0.11

SD, standard deviation; IQR, interquartile range; GOO, gastric outlet obstruction; DVT, deep vein thrombosis.

1

Developed additional adverse events.

2

Indicates statistical significance.